1. Home
  2. TECX vs LAES Comparison

TECX vs LAES Comparison

Compare TECX & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$20.50

Market Cap

413.3M

Sector

N/A

ML Signal

N/A

Logo SEALSQ Corp

LAES

SEALSQ Corp

N/A

Current Price

$0.97

Market Cap

368.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
TECX
LAES
Founded
2019
2022
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
413.3M
368.9M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
TECX
LAES
Price
$20.50
$0.97
Analyst Decision
Strong Buy
Buy
Analyst Count
10
2
Target Price
★ $71.00
$5.88
AVG Volume (30 Days)
158.1K
★ 3.7M
Earning Date
11-05-2026
09-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 40.70
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$59.43
Revenue Next Year
N/A
$41.92
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.77
$1.01
52 Week High
$39.53
$5.48

Technical Indicators

Market Signals
Indicator
TECX
LAES
Relative Strength Index (RSI) 44.54 27.57
Support Level $20.52 N/A
Resistance Level $22.95 $2.56
Average True Range (ATR) 1.29 0.12
MACD 0.19 -0.01
Stochastic Oscillator 44.43 3.16

Price Performance

Historical Comparison
TECX
LAES

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

Share on Social Networks: